Read Larry Connors' blog – Short Term Trading Strategies
Dr. Tradonsky noted, "The patient previously had a partial meniscectomy and was returning for an ACL reconstruction. Based on his ongoing symptoms, it was a wonderful opportunity to offer a new option that previously was not available prior to the Menaflex clearance."
"We're delighted to provide veterans and active armed forces a new alternative to the permanent loss of tissue associated with partial meniscectomy," noted Jeff Chandler, ReGen's Senior VP of Sales and Marketing. "Partial meniscectomy is the highest volume surgical orthopedic knee procedure, and now surgeons have the option to put something back when tissue is removed from patients with either chronic or acute injuries."
Many of the over 120 surgeons trained in the use of the Menaflex implant are now actively seeking patients and incorporating the new device into their protocol for treating patients with similar chronic meniscal injuries. A list of trained surgeons can be accessed at www.menaflex.com.
About the VA San Diego Healthcare System
The San Diego VA provides comprehensive health care for veterans at the medical center in La Jolla and at five community clinics located in Chula Vista, Escondido, Imperial Valley, Mission Valley and Vista. For more information please visit www.sandiego.va.gov.
About San Diego Sports Medicine
San Diego Sports Medicine and Orthopaedic Center (SDSM) was founded by James P. Tasto, M.D. All staff physicians are members of the American Academy of Orthopedic Surgeons. SDSM also hosts a nationally respected fellowship program that provides advanced training for orthopaedic surgeons in the fields of sports medicine and arthroscopy. Visit www.sdsm.net for additional information.
About ReGen Biologics, Inc.:
ReGen Biologics is an orthopedic products company that develops, manufactures and markets innovative tissue growth and repair products for U.S. and global markets. ReGen's Menaflex(TM) collagen meniscus implant employs proprietary biological collagen scaffold technology to facilitate tissue growth, thereby reinforcing and repairing the damaged meniscus of the knee. The FDA cleared the Menaflex device for marketing in the United States in December 2008. Visit www.regenbio.com and www.menaflex.com for more information.
SOURCE: ReGen Biologics
For ReGen Biologics, Inc. Donna Lucchesi, 480-634-6923 donna@LBCsuccess.com
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
